Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy

Launched by CENTRE ANTOINE LACASSAGNE · Sep 6, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring the effects of a new way to deliver proton therapy for certain types of cancers, including chordoma, chondrosarcoma, Ewing sarcoma, and osteosarcoma. Specifically, it aims to compare using one proton beam each day versus the traditional method of using two beams. Proton therapy is known for causing fewer side effects than other types of radiation therapy, and the goal of this study is to see if using just one beam can still effectively treat tumors while making the process easier and quicker for patients.

To be eligible for this trial, participants must be adults over 18 years old who have specific types of tumors requiring two beams of treatment and must have a recent MRI scan. They should also be in generally good health and have healthcare insurance. Participants can expect to undergo proton therapy with either one or two beams and will be closely monitored throughout the study. It's important to know that the trial is currently recruiting participants, and those interested should carefully review the information provided and discuss it with their healthcare provider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Chordoma, chondrosarcoma of the skull base and spine, Ewing's sarcoma, and osteosarcoma meeting the criteria for treatment by proton therapy
• • Tumour requiring 2 beams
• • MRI less than one month old
• • PS 0-2.
• • Patient who has read the patient information note and signed the consent form.
• • Patient with healthcare insurance cover.
• • Age over 18 years.
• • For women of childbearing age, negative urine pregnancy test and effective contraception in place for the duration of treatment and for six months following the end of treatment.
• Exclusion Criteria:
• • Persons deprived of their liberty or under guardianship.
• • Unable to undergo the medical follow-up of the clinical investigation for geographical, social or psychological reasons.
• • Patient eligible for symptom reduction surgery Vulnerable populations and participants defined in Articles 64 to 68 of Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017.